Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.

ABSTRACT:

Background

Available therapies for castrate-resistant prostate cancer (CRPC) confer minimal survival advantage; thus, there is interest in metastasis-directed therapy (MDT) for oligometastatic or oligoprogressive disease to improve outcomes. Here, we describe outcomes of oligoprogressive CRPC treated with stereotactic ablative radiotherapy (SABR).

Objective

To report outcomes of oligoprogressive CRPC treated with MDT using SABR.

Design, setting, and participants

Patients with oligoprogressive CRPC were retrospectively evaluated, and outcomes following MDT were reported. Outcomes were additionally compared with oligoprogressive CRPC treated with change in systemic therapy alone.

Intervention

SABR to oligoprogressive lesions.

Outcome measurements and statistic

SUBMITTER: Deek MP 

PROVIDER: S-EPMC7788526 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature